RxDoctor Payments Data

Flor Arellano, NP

Family · Glendale, AZNPI 1952025470

Payments from drug & device makers

$702in general payments, 2019–2025

Across 23 payments — averaging $30.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$148
  • Novo Nordisk$133
  • Phadia US Inc.$128
  • Exact Sciences$122
  • Medtronic$45
  • Recordati_rare_diseases_inc.$35
  • plus $92 from 4 others

What the payments were for

  • Food & beverage$702100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$702 in reported general payments places this provider in the 60th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$11,159
Medicare patients
33
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide34$47,483
JardianceEmpagliflozin17$29,598
OzempicSemaglutide22$22,804
JanuviaSitagliptin Phosphate12$13,665
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,768
LantusInsulin Glargine,hum.Rec.Anlog21$2,064
Gabapentin69$1,508
Atorvastatin Calcium129$993
Famotidine33$972
Losartan Potassium84$882
Rosuvastatin Calcium40$730
Metformin Hcl110$684
Lisinopril92$597
Pioglitazone Hcl46$571
Omeprazole25$524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$29,59817 claims
Novo NordiskOzempic$133$22,80422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,119 family providers in Arizona.

Other family in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →